Pfizer Pulls Plug But iTeos Has High Hopes For IDO1 Inhibitor

 
• By Kevin Grogan

The Belgian biotech has regained the rights to an early-stage IDO1 inhibitor that has failed a Phase I trial but iTeos believes the drug's penetration to the brain makes EOS200271 a significant asset.

Doors
Door closes, another opens: iTeos upbeat despite Pfizer pact ending • Source: Shutterstock

More from Immuno-oncology

More from Anticancer